10-Q: Harmony Biosciences: Q3 Growth, Pipeline Progress, ZYN002 Setback

Harmony Biosciences reported strong financial growth in Q3 2025, driven by WAKIX sales, while advancing its diverse neurological pipeline despite a Phase 3 setback for ZYN002.

Summary

• Net product revenue increased by 28.7% to $239.455 million for the three months ended September 30, 2025, and by 21.7% to $624.677 million for the nine months ended September 30, 2025, compared to the same periods in 2024.
• Net income grew by 10.3% to $50.865 million for the three months and by 41.9% to $136.201 million for the nine months ended September 30, 2025.
• Diluted earnings per share were $0.87 for the three months and $2.32 for the nine months ended September 30, 2025.
• Research and development expenses significantly increased by 116.5% to $54.962 million for the three months and by 25.6% to $139.661 million for the nine months, primarily due to IPR&D charges and clinical trial advancements.
• The Phase 3 RECONNECT study for ZYN002 in Fragile X Syndrome did not meet its primary endpoint, leading to a pause in the 22q deletion syndrome study.
• Settlement agreements were reached with Lupin, Annora, and Novugen Pharma in ANDA litigation, allowing generic WAKIX sales to begin in January 2030.
• The company had $778.4 million in cash, cash equivalents, and investments as of September 30, 2025, and believes it has sufficient liquidity for at least the next 12 months.
• The 'One Big Beautiful Bill Act' (OBBBA) enacted July 4, 2025, resulted in a $48.0 million reduction to deferred tax assets related to domestic R&D expenses, reducing 2025 federal tax payments.

Sentiment

Score: 7

Explanation: The company exhibits strong financial performance and active pipeline development, particularly with its lead product WAKIX and several promising early-to-mid-stage assets. The ANDA settlements provide significant clarity and extended market exclusivity. However, the notable failure of the ZYN002 Phase 3 trial for Fragile X Syndrome introduces a material setback for a key acquired asset and highlights inherent R&D risks, tempering overall positive sentiment.

Positives

• Strong net product revenue growth of 28.7% for the quarter and 21.7% for the nine months, driven by a 26.8% increase in WAKIX units shipped and a 7.0% price increase.
• Significant increase in net income by 10.3% for the quarter and 41.9% for the nine months.
• Robust cash position with $778.4 million in cash, cash equivalents, and investments as of September 30, 2025.
• Successful FDA approval of WAKIX for excessive daytime sleepiness (EDS) in pediatric patients six years and older with narcolepsy in June 2024.
• Settlement of ANDA litigation with Lupin, Annora, and Novugen Pharma, delaying generic WAKIX entry until January 2030, providing patent protection longevity.
• Advancement of multiple pipeline candidates, including initiation of Phase 3 TEMPO study for pitolisant in Prader-Willi syndrome (PWS) and positive preclinical data for BP1.15205.
• New tax legislation (OBBBA) resulted in a $48.0 million reduction to deferred tax assets, reducing federal tax payments for 2025.
• Initiation of pivotal bioequivalence study for Pitolisant GR in Q1 2025 with topline data anticipated in Q4 2025, and IND submission for Pitolisant HD with Phase 3 trials planned for Q4 2025.

Negatives

• The Phase 3 RECONNECT study for ZYN002 in Fragile X Syndrome did not meet its primary endpoint, primarily due to a higher than expected placebo response rate.
• The Phase 3 study for ZYN002 in 22q deletion syndrome has been paused following the FXS trial results.
• The FDA did not approve the sNDA seeking to expand the WAKIX label for the treatment of pediatric patients with cataplexy in June 2024, requiring a resubmission.
• Cost of product sales as a percentage of net product revenue increased to 24.9% for the three months and 20.8% for the nine months ended September 30, 2025, due to triggering a higher royalty tier earlier in the year.

Risks

• Clinical trial results of product candidates may not be successful, as demonstrated by the ZYN002 Phase 3 trial.
• Ability to obtain regulatory approval for new indications or product candidates is uncertain and subject to FDA review.
• Competition from products manufactured and sold or being developed by other companies, including generic competition, could impact WAKIX sales after patent expiration.
• Dependence on a single supplier for the active pharmaceutical ingredient (API) for WAKIX and other product candidates poses supply chain risks.
• ANDA litigation, despite recent settlements, continues for other generic manufacturers, and unfavorable outcomes could significantly impact operations.
• Significant time and capital are required for product development, and there is no assurance that research and development efforts will result in successfully commercialized products beyond WAKIX.
• The company's liquidity and cash flow projections are based on assumptions that may prove incorrect, potentially leading to faster capital resource utilization.

Future Outlook

The company anticipates continued growth in WAKIX sales and expects sales and marketing expenses to increase to support this growth and potential new indications. Significant research and development expenses are projected as the company advances its clinical programs, including the Phase 3 TEMPO study for pitolisant in PWS, pivotal bioequivalence study for Pitolisant GR (topline data Q4 2025, PDUFA Q1 2027), and Phase 3 registrational trials for Pitolisant HD (Q4 2025 initiation, PDUFA 2028). First-in-human studies for BP1.15205 are expected to begin in Q4 2025 with topline data in 2026. The company is evaluating next steps for the ZYN002 Fragile X Syndrome program following the Phase 3 setback and has paused the 22q deletion syndrome study. The company believes its existing liquidity will meet operational needs for at least the next 12 months.

Management Comments

• We are cultivating a differentiated neuroscience company, rooted in innovation and driven by a commitment to addressing the unmet needs of patients living with neurological diseases.
• We are harnessing scientific insights and pioneering approaches to advance meaningful treatments that help patients thrive.
• We remain committed to obtaining pediatric exclusivity for WAKIX, supported by the PWS Phase 3 registrational trial and current data in pediatric narcolepsy.
• We believe our existing cash, cash equivalents and investments on hand will enable us to meet our operational liquidity needs and fund potential investing activities for at least the next 12 months.

Industry Context

Harmony Biosciences operates in the rare neurological diseases segment, a specialized area with significant unmet medical needs. The company's focus on expanding its portfolio beyond its lead product, WAKIX, into areas like rare epilepsy (Dravet Syndrome, Lennox-Gastaut Syndrome) and neurobehavioral disorders (Fragile X Syndrome, 22q deletion syndrome) reflects a broader industry trend of pharmaceutical companies seeking to diversify revenue streams and address orphan diseases. The development of next-generation formulations of pitolisant and novel mechanisms like orexin-2 receptor agonists and cell replacement therapy indicates a commitment to innovation in a competitive landscape where intellectual property protection and regulatory approvals are critical for market success.

Comparison to Industry Standards

• NA

Legal Proceedings

• Ongoing ANDA litigation against Novitium Pharma LLC, Zenara Pharma Pvt. Ltd., AET Pharma US, Inc., and MSN Pharmaceuticals Inc. regarding generic versions of WAKIX.
• Settlement agreements reached with Lupin Limited, Annora Pharma Private Limited, and Novugen Pharma Sdn. Bhd., allowing them to sell generic WAKIX beginning January 2030, or earlier under certain circumstances.
• A four-day bench trial for the consolidated ANDA cases is scheduled to begin on February 17, 2026.

Related Party Transactions

• The company has a right-of-use agreement with Paragon Biosciences, LLC (Paragon) for office space and received consulting services from Paragon, incurring $0.1 million for the three months and $0.4 million for the nine months ended September 30, 2025. Paragon shares common ownership with the company, and its Founder, Chairman, and CEO is also the Chairman of the company's board of directors.
• In June 2025, the company entered into a research collaboration, option and license agreement (CiRC Agreement) with CiRC Biosciences, Inc. (CiRC), an entity controlled by Paragon. An upfront fee of $15.0 million was paid to CiRC, with potential future research milestones, option exercise fees, and sales-based milestones and royalties.

Stakeholder Impact

• Shareholders: Positive impact from strong revenue and net income growth, extended WAKIX exclusivity due to ANDA settlements, but negative impact from the ZYN002 Phase 3 failure and associated pipeline pause.
• Patients: Potential for new treatments for narcolepsy (pediatric EDS approval, next-gen pitolisant, orexin agonist), Prader-Willi syndrome, Dravet Syndrome, Lennox-Gastaut Syndrome, and other neurological diseases, but a setback for Fragile X Syndrome patients with ZYN002.
• Employees: Increased headcount and personnel costs indicate growth, but the ZYN002 setback may impact specific R&D teams.
• Creditors: Strong cash position and compliance with debt covenants indicate good financial health.
• Suppliers: Continued dependence on single API suppliers for WAKIX and pipeline candidates poses concentration risk.

Next Steps

• Determine next steps for the ZYN002 Fragile X Syndrome program following the Phase 3 RECONNECT study failure.
• Continue Phase 3 registrational trial (TEMPO study) for pitolisant in Prader-Willi syndrome (PWS).
• Anticipate topline data readout from the Pitolisant GR pivotal bioequivalence study in Q4 2025.
• Initiate Phase 3 registrational trials for Pitolisant HD in narcolepsy and idiopathic hypersomnia (IH) in Q4 2025.
• Begin first-in-human studies for the orexin-2 receptor agonist (BP1.15205) in Q4 2025, with topline data anticipated in 2026.
• Continue two Phase 3 registrational clinical trials for EPX-100 (ARGUS Study for Dravet Syndrome and LIGHTHOUSE Study for Lennox-Gastaut Syndrome).
• Advance EPX-200 (liquid lorcaserin formulation) through the pre-IND phase for developmental and epileptic encephalopathies (DEEs).
• Continue to defend against remaining ANDA litigation, with a four-day bench trial scheduled for February 17, 2026.

Key Dates

Recommendation

Harmony Biosciences demonstrates robust financial performance driven by its flagship product, WAKIX, and has successfully extended its market exclusivity through ANDA settlements. The company is actively investing in a diversified pipeline across rare neurological diseases, which presents significant long-term growth potential. However, the recent Phase 3 failure of ZYN002 for Fragile X Syndrome is a material setback for a key acquired asset, introducing uncertainty and risk to that specific program. While the core business is strong and other pipeline assets are progressing, the ZYN002 outcome warrants a cautious stance. Investors should hold to monitor the company's ability to mitigate the ZYN002 setback, advance its remaining pipeline, and maintain WAKIX's growth trajectory.

Keywords

Harmony Biosciences, WAKIX, Narcolepsy, Pitolisant, Rare Neurological Diseases, Fragile X Syndrome, Dravet Syndrome, Lennox-Gastaut Syndrome, Orexin, Epilepsy, Biopharma, SEC 10-Q, ZYN002, EPX-100